Pfizer has reported its first-quarter 2026 earnings, exceeding market expectations with $14.5 billion in revenue. The company reaffirmed its full-year guidance, bolstered by a 22% operational growth in launched and acquired products.
Amgen has reported a robust start to the year, with its Q1 2026 financial results exceeding analyst estimates. Total revenue climbed to $8.6 billion, driven by double-digit growth across 16 key brands and a promising expansion of the MariTide obesity program.
The recent STELARA FDA approval provides a crucial new non-TNF biologic treatment option for children two years and older suffering from moderately to severely active Crohn’s disease.
Eli Lilly and Company’s Q1 2026 results showcased a 56% revenue surge to $19.8 billion, driven by unparalleled demand for its incretin portfolio and breakthrough oncology treatments.
Biogen reported a solid start to the year with its Q1 2026 results, featuring 12% growth in new products and a major move to acquire Apellis Pharmaceuticals to bolster its rare disease and nephrology portfolios.
AbbVie announced its first-quarter 2026 financial results, surpassing expectations with $15 billion in revenue and raising its full-year EPS guidance as next-generation immunology assets continue to offset Humira’s erosion.
Novo Nordisk will present 52 abstracts at the European Congress on Obesity, showcasing a portfolio that includes high-dose Wegovy and new data on women’s health during menopause.
AstraZeneca reports a robust start to 2026 with $15.3 billion in total revenue, driven by its powerhouse oncology and rare disease portfolios, alongside key clinical successes in COPD and hypophosphatasia.
Gilead Sciences has finalized its $7.8 billion acquisition of Arcellx, Inc., positioning the company for the potential 2026 commercial launch of the BCMA-directed CAR T-cell therapy, anito-cel.
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
